This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cigarette smoking is the most common form of nicotine use, causes significant morbidity and mortality and has been described as the single most preventable cause of death in the United States (US Department of Health and Welfare, 1979; 1990). Even though rates of smoking have declined among adolescents recently, it is an area of considerable public health concern since about 17% of high-school seniors smoke daily (Johnston et al., 2002). It has been estimated that 3,000 adolescents start to smoke every day. Tobacco is often one of the first drugs tried by individuals who later use illicit drugs (Kandel et al., 1978; Kandel and Yamaguchi, 1993), and 80% of adult smokers become addicted to tobacco by age 18 (American Health Association, 1995). In the current proposal, we intend to study the efficacy of bupropion SR with or without combined contingency management (CM) among adolescent cigarette smokers. The proposed study will test not only medication (bupropion SR), but also combination of medication and CM in potentially improving smoking cessation outcomes AND retention of adolescent smokers in the study.